Showing 2571-2580 of 3223 results for "".
- Nidek and Hoya Vision Care Enter Global Partnershiphttps://modernod.com/news/nidek-and-hoya-vision-care-enter-global-partnership/2481381/Nidek has announced a partnership with Hoya Vision Care that would allow Hoya's customers access to Nidek's optical products, services and instruments through both local distributors. Financial terms of the deal were not disclosed. The aim of the partnership
- Roche Names Teresa Graham Head of its Pharma Businesshttps://modernod.com/news/roche-names-teresa-graham-head-of-its-pharma-business/2481379/Teresa Graham, former Genentech executive and current Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO of Roche Pharmaceuticals, based in Basel, Switzerland, effective March 2023. She will also become a member of the Corporate Executive Committee.</
- Study: Maintaining the Enzyme ACE2 in the Gut May Prevent Diabetic Blindnesshttps://modernod.com/news/type-1-diabetes-maintaining-the-enzyme-ace2-in-the-gut-prevents-diabetic-blindness/2481360/A new study from the University of Alabama at Birmingham shows that the progressive damage to blood vessels in the light-sensitive tissue at the back of the eye may be due to a leaky small intestine that weakens the barrier between gut bacteria and the blood system. The study publi
- Acelyrin Acquires ValenzaBio, Maker of Treatment Candidate for Thyroid Eye Diseasehttps://modernod.com/news/acelyrin-acquires-valenzabio-maker-of-treatment-candidate-for-thyroid-eye-disease/2481339/Acelyrin announced the acquisition of ValenzaBio, a privately held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction. Financial terms of the deal were not disclosed. The acquisition of ValenzaBi
- Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol-in-presbyopia/2481333/Ocuphire Pharma announced the initiation of the VEGA-2 phase 3 pivotal trial with the first patient enrolled in late December. VEGA-2 is evaluating the efficacy and safety for two labels: Nyxol alone and Nyxol with adjunctive low-dose pilocarpine (LDP) therapy for presbyopia.
- Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directorshttps://modernod.com/news/iveric-bio-announces-the-addition-of-pravin-u-dugel-md-to-its-board-of-directors/2481317/Iveric bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the company’s business strategy and in overseeing the development and regulatory submission
- AAO: Prior Authorization Reform Effort Gets Boost from CMShttps://modernod.com/news/aao-prior-authorization-reform-effort-gets-boost-from-cms/2481310/The Centers for Medicare & Medicaid Services (CMS) released a proposed rule that "closely aligns" with the Improving Seniors’ Timely Access to Care Act (S. 3018/H.R. 3173), a bill the American Academy of Ophthalmology helped craft, according to an AAO news release. If ado
- Verana Health Study of Patients with Dry AMD Published in International Ophthalmologyhttps://modernod.com/news/verana-health-study-of-patients-with-dry-amd-published-in-international-ophthalmology/2481301/Verana Health—a digital health company elevating quality in real-world data—announced that Ophthalmology and Therapy, an international, peer-reviewed medical journal, has
- Pixium Vision Completes Implantations in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-completes-implantations-in-the-european-pivotal-trial-primavera/2481297/Pixium Vision SA announced the completion of implantations in all the patients enrolled in the PRIMAvera European pivotal trial in geographic atrophy. A total of 38 patients have been implanted with the Prima System in the PRIMAvera study (NCT04676854), an open-label, baseline
- Thea Pharma Announces FDA Approval of Glaucoma Drug Iyuzehhttps://modernod.com/news/thea-pharma-announces-fda-approval-of-glaucoma-drug-iyuzeh/2481294/Thea Pharma announced FDA approval of Iyuzeh (latanoprost ophthalmic solution) 0.005% for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Iyuzeh is the first and only clinically proven formulation of latanoprost available in the Unite